APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Attenuated Vaccine Market Outlook and Growth Opportunities 2026

Report ID 173968240430 December 2025194 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Attenuated Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Attenuated Vaccine market include Changchun BCHT Biotechnology Co.,Ltd, Shanghai Rongsheng Biotech, Sanofi, Johnson & Johnson, Merck & Co., Pfizer Inc, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd. and Green Cross Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Attenuated Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Attenuated Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Attenuated Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Attenuated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Attenuated Vaccine Segment by Company

Changchun BCHT Biotechnology Co.,Ltd

Shanghai Rongsheng Biotech

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer Inc

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Green Cross Corporation

CSL Limited

Biken

Astellas Pharma

Attenuated Vaccine Segment by Type

Bacterial Vaccine

Viral Vaccine

Attenuated Vaccine Segment by Application

Hospital

Clinic

Others

Attenuated Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Attenuated Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Attenuated Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Attenuated Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Attenuated Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Attenuated Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Attenuated Vaccine industry.

Chapter 3: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Attenuated Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Attenuated Vaccine Industry Trends Table 2. Attenuated Vaccine Industry Drivers Table 3. Attenuated Vaccine Industry Opportunities and Challenges Table 4. Attenuated Vaccine Industry Restraints Table 5. Global Attenuated Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Attenuated Vaccine Revenue Share by Company (2021-2026) Table 7. Global Attenuated Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Attenuated Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Attenuated Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Attenuated Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Attenuated Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Attenuated Vaccine Company, Product Type & Application Table 13. Global Attenuated Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Attenuated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Bacterial Vaccine Table 18. Significant Companies of Viral Vaccine Table 19. Global Attenuated Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Attenuated Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Attenuated Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Attenuated Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Attenuated Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Attenuated Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Attenuated Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Attenuated Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Attenuated Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Attenuated Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Attenuated Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Attenuated Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Attenuated Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Attenuated Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Attenuated Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Attenuated Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Attenuated Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Attenuated Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Attenuated Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Attenuated Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Attenuated Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Attenuated Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Attenuated Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Attenuated Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Attenuated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Attenuated Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Attenuated Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Attenuated Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Attenuated Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Attenuated Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Attenuated Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Attenuated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Global Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Attenuated Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Attenuated Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Attenuated Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Attenuated Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Attenuated Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Changchun BCHT Biotechnology Co.,Ltd Company Information Table 65. Changchun BCHT Biotechnology Co.,Ltd Business Overview Table 66. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio Table 68. Changchun BCHT Biotechnology Co.,Ltd Recent Development Table 69. Shanghai Rongsheng Biotech Company Information Table 70. Shanghai Rongsheng Biotech Business Overview Table 71. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio Table 73. Shanghai Rongsheng Biotech Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sanofi Attenuated Vaccine Product Portfolio Table 78. Sanofi Recent Development Table 79. Johnson & Johnson Company Information Table 80. Johnson & Johnson Business Overview Table 81. Johnson & Johnson Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Johnson & Johnson Attenuated Vaccine Product Portfolio Table 83. Johnson & Johnson Recent Development Table 84. Merck & Co. Company Information Table 85. Merck & Co. Business Overview Table 86. Merck & Co. Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck & Co. Attenuated Vaccine Product Portfolio Table 88. Merck & Co. Recent Development Table 89. Pfizer Inc Company Information Table 90. Pfizer Inc Business Overview Table 91. Pfizer Inc Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Pfizer Inc Attenuated Vaccine Product Portfolio Table 93. Pfizer Inc Recent Development Table 94. GlaxoSmithKline plc Company Information Table 95. GlaxoSmithKline plc Business Overview Table 96. GlaxoSmithKline plc Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. GlaxoSmithKline plc Attenuated Vaccine Product Portfolio Table 98. GlaxoSmithKline plc Recent Development Table 99. Serum Institute of India Pvt. Ltd. Company Information Table 100. Serum Institute of India Pvt. Ltd. Business Overview Table 101. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio Table 103. Serum Institute of India Pvt. Ltd. Recent Development Table 104. Green Cross Corporation Company Information Table 105. Green Cross Corporation Business Overview Table 106. Green Cross Corporation Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Green Cross Corporation Attenuated Vaccine Product Portfolio Table 108. Green Cross Corporation Recent Development Table 109. CSL Limited Company Information Table 110. CSL Limited Business Overview Table 111. CSL Limited Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. CSL Limited Attenuated Vaccine Product Portfolio Table 113. CSL Limited Recent Development Table 114. Biken Company Information Table 115. Biken Business Overview Table 116. Biken Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Biken Attenuated Vaccine Product Portfolio Table 118. Biken Recent Development Table 119. Astellas Pharma Company Information Table 120. Astellas Pharma Business Overview Table 121. Astellas Pharma Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Astellas Pharma Attenuated Vaccine Product Portfolio Table 123. Astellas Pharma Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Attenuated Vaccine Distributors List Table 127. Attenuated Vaccine Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Attenuated Vaccine Product Image Figure 2. Global Attenuated Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Attenuated Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Attenuated Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Attenuated Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Bacterial Vaccine Image Figure 10. Viral Vaccine Image Figure 11. Global Attenuated Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Attenuated Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Attenuated Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Attenuated Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Attenuated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Attenuated Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Attenuated Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Attenuated Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Attenuated Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Attenuated Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Attenuated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Attenuated Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Attenuated Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Attenuated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Attenuated Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Attenuated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Attenuated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Attenuated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Attenuated Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Attenuated Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial Vaccine
  • Viral Vaccine
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Changchun BCHT Biotechnology Co.,Ltd
  • Shanghai Rongsheng Biotech
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Green Cross Corporation
  • CSL Limited
  • Biken
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Attenuated Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Attenuated Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Attenuated Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Attenuated Vaccine Market Dynamics
  1. 2.1 Attenuated Vaccine Industry Trends
  2. 2.2 Attenuated Vaccine Industry Drivers
  3. 2.3 Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine Industry Restraints
3 Attenuated Vaccine Market by Company
  1. 3.1 Global Attenuated Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Attenuated Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Attenuated Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Attenuated Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Attenuated Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Attenuated Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Attenuated Vaccine Company Product Type and Application
  8. 3.8 Global Attenuated Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Attenuated Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Attenuated Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Attenuated Vaccine Market by Type
  1. 4.1 Attenuated Vaccine Type Introduction
  2. 4.1.1 Bacterial Vaccine
  3. 4.1.2 Viral Vaccine
  4. 4.2 Global Attenuated Vaccine Sales Volume by Type
  5. 4.2.1 Global Attenuated Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Attenuated Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Attenuated Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Attenuated Vaccine Sales Value by Type
  9. 4.3.1 Global Attenuated Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Attenuated Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Attenuated Vaccine Sales Value Share by Type (2021-2032)
5 Attenuated Vaccine Market by Application
  1. 5.1 Attenuated Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Attenuated Vaccine Sales Volume by Application
  6. 5.2.1 Global Attenuated Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Attenuated Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Attenuated Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Attenuated Vaccine Sales Value by Application
  10. 5.3.1 Global Attenuated Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Attenuated Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Attenuated Vaccine Sales Value Share by Application (2021-2032)
6 Attenuated Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Attenuated Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Attenuated Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Attenuated Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Attenuated Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Attenuated Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Attenuated Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Attenuated Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Attenuated Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Attenuated Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Attenuated Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Attenuated Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Attenuated Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Attenuated Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Attenuated Vaccine Sales Value Share by Country, 2025 VS 2032
7 Attenuated Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Attenuated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Attenuated Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Attenuated Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Attenuated Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Attenuated Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Attenuated Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Attenuated Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Attenuated Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Attenuated Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Attenuated Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun BCHT Biotechnology Co.,Ltd
  2. 8.1.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
  3. 8.1.2 Changchun BCHT Biotechnology Co.,Ltd Business Overview
  4. 8.1.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio
  6. 8.1.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments
  7. 8.2 Shanghai Rongsheng Biotech
  8. 8.2.1 Shanghai Rongsheng Biotech Company Information
  9. 8.2.2 Shanghai Rongsheng Biotech Business Overview
  10. 8.2.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio
  12. 8.2.5 Shanghai Rongsheng Biotech Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Attenuated Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Attenuated Vaccine Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Merck & Co.
  26. 8.5.1 Merck & Co. Company Information
  27. 8.5.2 Merck & Co. Business Overview
  28. 8.5.3 Merck & Co. Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co. Attenuated Vaccine Product Portfolio
  30. 8.5.5 Merck & Co. Recent Developments
  31. 8.6 Pfizer Inc
  32. 8.6.1 Pfizer Inc Company Information
  33. 8.6.2 Pfizer Inc Business Overview
  34. 8.6.3 Pfizer Inc Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Inc Attenuated Vaccine Product Portfolio
  36. 8.6.5 Pfizer Inc Recent Developments
  37. 8.7 GlaxoSmithKline plc
  38. 8.7.1 GlaxoSmithKline plc Company Information
  39. 8.7.2 GlaxoSmithKline plc Business Overview
  40. 8.7.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline plc Attenuated Vaccine Product Portfolio
  42. 8.7.5 GlaxoSmithKline plc Recent Developments
  43. 8.8 Serum Institute of India Pvt. Ltd.
  44. 8.8.1 Serum Institute of India Pvt. Ltd. Company Information
  45. 8.8.2 Serum Institute of India Pvt. Ltd. Business Overview
  46. 8.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio
  48. 8.8.5 Serum Institute of India Pvt. Ltd. Recent Developments
  49. 8.9 Green Cross Corporation
  50. 8.9.1 Green Cross Corporation Company Information
  51. 8.9.2 Green Cross Corporation Business Overview
  52. 8.9.3 Green Cross Corporation Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Green Cross Corporation Attenuated Vaccine Product Portfolio
  54. 8.9.5 Green Cross Corporation Recent Developments
  55. 8.10 CSL Limited
  56. 8.10.1 CSL Limited Company Information
  57. 8.10.2 CSL Limited Business Overview
  58. 8.10.3 CSL Limited Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CSL Limited Attenuated Vaccine Product Portfolio
  60. 8.10.5 CSL Limited Recent Developments
  61. 8.11 Biken
  62. 8.11.1 Biken Company Information
  63. 8.11.2 Biken Business Overview
  64. 8.11.3 Biken Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Biken Attenuated Vaccine Product Portfolio
  66. 8.11.5 Biken Recent Developments
  67. 8.12 Astellas Pharma
  68. 8.12.1 Astellas Pharma Company Information
  69. 8.12.2 Astellas Pharma Business Overview
  70. 8.12.3 Astellas Pharma Attenuated Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Astellas Pharma Attenuated Vaccine Product Portfolio
  72. 8.12.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Attenuated Vaccine Value Chain Analysis
  2. 9.1.1 Attenuated Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Attenuated Vaccine Sales Mode & Process
  6. 9.2 Attenuated Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Attenuated Vaccine Distributors
  9. 9.2.3 Attenuated Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst